Primary hyperoxaluria type 1 in Tunisian children

##plugins.themes.academic_pro.article.sidebar##

Published Feb 7, 2011
Download
pdf
Vol. 89 No. 2 (2011): Issue Feb 2011

##plugins.themes.academic_pro.article.main##

Tahar Gargah
Nourchène Khelil
Youssef Gharbi
Wiem Karoui
Monique Trabelsi
Hatem Rajhi
Jaouida Abdelmoula
Mohamed Rachid Lakhoua

Abstract

Background: Primary hyperoxaliuria type 1 is an autosomalrecessive disorder characterized by increasing urinary excretion of calcium oxalate, recurrent urolithiasis, nephrocalcinosis, and accumulation of insoluble oxalate throughout the body. This inborn error of metabolism appears to be a common cause of end stage renal disease in Tunisia.
Aims: To review the clinical, biological and radiological futures of primary hyperoxaluria type 1 and to correlate these aspects with the development of end-stage renal disease.
Methods: we retrospectively reviewed 44 children with Primary hyperoxaliuria type I who were treated in our department during a period of 15 years between 1995 and 2009. The diagnosis was established by quantitative urinary oxalate excretion. In patient with renal impairment, the diagnosis was made by infrared spectroscopy of stone or by renal biopsy.
Results: Male to female ratio was 1.2. The median age at diagnosis was 5.75 years. About 43 % of those were diagnosed before the age of 5 years. Initial symptoms were dominated by uraemia. Four patients were asymptomatic and diagnosed by sibling screening of known patients. Nephrocalcinosis was present in all patients. It is cortical in 34%, medullary in 32% and global in 34%. At diagnosis, twelve children were in end-stage renal disease (27%). Pyridoxine
response, which is defined by a reduction in urine oxalate excretion of 60% or more, was found in 27%.
Conclusion: In the majority of patients, the clinical expression of Primary hyperoxaliuria type 1 is characterized by nephrocalcinosis, urolithiasis and renal failure. Pyridoxine sensitivity is associated with better outcome.

Keywords:

Child, hyperoxaluria, nephrocalcinosis, pyridoxine responsiveness, end-stage renal disease

##plugins.themes.academic_pro.article.details##

References

  1. Danpure CJ. Metabolic and clinical heterogeneity of primary hyperoxaluria type 1. Am J Kidney Dis 1991;17: 366.
  2. Cochat P, Koch Nogueira PC, Mahmoud AM, Jamieson NV, Scheinman JI, Rolland MO. Primary hyperoxaluria in infants: medical, ethical and economic issues. J Pediatr 1999;135:749- 750.
  3. Cochat P, Liutkus A, Fargue S, Basmaison O, Ranchin B, Rolland MO. Primary hyperoxaluria type 1: still challenging! Pediatr Nephrol 2006; 21: 1075-1081.
  4. Bacchetta J, Fargue S, Boutroy S, et al. Bone metabolism in oxalosis: a single-center study using new imaging techniques and biomarkers. Pediatr Nephrol. 2010; 25:1081-89.
  5. Kammoun A, Lakhoua MR. end stage renal disease of the Tunisian child: epidemiology, etiology and outcome. Pediatr Nephrol 1996; 10:479-82.
  6. Marrakchi O, Belhaj R, Bahlous A, et al Urinary stones in Tunisian children: based on series of 187 cases. Prog Urol 2008, 18, 13, 1056-61.
  7. Schwartz GJ, Brion LP, Spitzer A. The use of plasma creatinine concentration for estimating glomerular filtration rate in infants, children, and adolescents. Pediatr Clin North Am 1987; 34:571-590.
  8. Dick PT, Shuckett BM, Daneman A, Kooh SW. Observer reliability in grading nephrocalcinosis on ultrasound examinations in children. Pediatr Radiol 1999;29:68-72.
  9. Williams E L, Acquaviva C, Amoroso, et al. Primary hyperoxaluria type 1: update and additional mutation analysis of the AGXT gene. Hum. Mutat 2009; 30: 910-17.
  10. Von Woerden SC, Groothoff JW, Wanders RJA, Davin JC, Wijburg FA. Primary hyperoxaluria type 1 in Netherlands: prevalence and outcome. Nephrol Dial Transplant 2003;18:273-79.
  11. Coulter-Mackie MB. Preliminary evidence for ethnic differences in primary hyperoxaluria type 1 genotype. Am J Nephrol 2005; 25:264-68.
  12. Belhadj R, Hayder N, Gargah T, et al. Biochemical and molecular diagnosis of primary hyperoxaluria type 1. Pathol Biol 2009 doi:10.1016.
  13. Amoroso A, Pirulli D, Florian Fet al. AGXT gene mutations and their influence on clinical heterogeneity of type 1 primary hyperoxaluria. J Am Soc Nephrol 2001;12: 2072-79.
  14. Khoo JJ, Pee S, Kamaludin DP..Infantile primary hyperoxaluria type 1 with end stage renal failure. Pathology 2006; 38: 371-74.
  15. Leumann E, Hoppe B. Primary hyperoxaluria type 1: is genotyping clinically helpful? Pediatr Nephrol 2005; 20:555-57.
  16. Milliner DS, Wilson DM, Smith LH. Phenotypic expression of primary hyperoxaluria: comparative features of types I and II. Kidney Int 2001 59:31-36.
  17. Diallo O, Janssens F, Hall M, Avni EF. Type 1 primary hyperoxaluria in pediatric patients: renal sonographic patterns. AJR 2004;183:1767-70.
  18. Cox KL, Filler G, Salvatierra O Jr, Esquivel CO. One hundred percent patient and kidney allograft survival with simultaneous liver and kidney transplantation in infants with primary hyperoxaluria: a single-center experience. Transplantation 2003; 76:1458-63.
  19. Monico CG, Rossetti S, Olson JB, Milliner DS. Pyridoxine effect in type I primary hyperoxaluria is associated with the most common mutant allele. Kidney Int 2005; 67:1704-9.
  20. Danpure CJ. Primary hyperoxaluria: from gene defects to designer drugs? Nephrol Dial Transplant 2005; 20:1525-29.